Kopran Limited

Kopran Limited, established on April 26, 1958, is an integrated pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company specializes in the development, manufacture, and marketing of both active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, syrups, and injectables. Kopran's diverse product portfolio encompasses a wide range of therapeutic categories, such as macrolides, antibacterials, anticonvulsants, antihypertensives, and anti-infectives.

As of March 12, 2026, Kopran Limited's stock is listed on the National Stock Exchange of India under the ticker symbol KOPRAN, with a closing price of ₹122.01. The company reported a revenue of ₹63,359 lakhs for the fiscal year 2024-25, with an EBITDA of ₹7,290 lakhs and a profit after tax of ₹3,855 lakhs. Kopran employs a team of over 800 professionals, reflecting its commitment to quality and innovation in the pharmaceutical industry.

Kopran Limited operates state-of-the-art manufacturing facilities in India, strategically located to support its diverse product range. The company's API manufacturing plant is situated in Mahad, Maharashtra, while its finished dosage forms are produced at the Khopoli facility, also in Maharashtra. These facilities are equipped with advanced technology and adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical products.

The leadership team at Kopran Limited is headed by Executive Vice Chairman Mr. Surendra Somani, who has been with the company since 1981 and brings extensive experience in the pharmaceutical industry. Other key executives include Mr. Basant Kumar Soni, the Chief Financial Officer, and Mr. Ajit Jain, the Chief Operating Officer. The Board of Directors comprises individuals with diverse expertise, including independent directors such as Mrs. Mamta Biyani and Mr. Narayan Atal, who contribute to the company's strategic direction and governance.

Kopran Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold certifications from various regulatory bodies, such as the EU GMP, MHRA (UK), and Health Canada, facilitating market access in these regions. Additionally, Kopran's products are approved by the FDA in the United States and the TGA in Australia, demonstrating compliance with international quality standards.

Kopran Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in over 60 countries, including regions such as South Africa, Mexico, China, and the United Kingdom. This global reach is supported by the company's WHO GMP certification, which enhances its ability to meet the quality standards required for market entry in these regions.

Kopran Limited's geographic strategy demonstrates a balanced approach to market diversification. While the company has a strong presence in regulated markets, it has also made significant inroads into emerging markets, mitigating concentration risk. This strategic diversification allows Kopran to leverage growth opportunities across different regions, aligning with its mission to provide affordable medicines globally.

Kopran Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), indicating compliance with U.S. regulatory standards. The company has received approvals for its Abbreviated New Drug Applications (ANDAs), allowing it to market generic formulations in the U.S. market. Additionally, Kopran has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes of its APIs. The company's facilities have undergone FDA inspections, reflecting its commitment to maintaining high-quality manufacturing practices.

Kopran Limited's manufacturing facilities hold certifications from the World Health Organization's Good Manufacturing Practices (WHO GMP) and the European Union's Good Manufacturing Practices (EU GMP). These certifications affirm the company's adherence to international quality standards, facilitating access to global markets and reinforcing its reputation for quality and reliability.

In India, Kopran Limited's manufacturing facilities are licensed by the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with national regulatory requirements. The company also holds approvals from various state drug controllers and has obtained export No Objection Certificates (NOCs), enabling it to export pharmaceutical products to multiple countries. These regulatory approvals underscore Kopran's commitment to maintaining high-quality standards in its manufacturing processes.

As of March 28, 2026, there are no publicly available records indicating that Kopran Limited has received any Form 483 observations, warning letters, or import alerts from regulatory authorities such as the FDA. This absence of adverse regulatory actions suggests that the company maintains a strong compliance record and adheres to the regulatory standards set by health authorities.

Kopran Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. In the generic formulations segment, it competes with companies like Cipla, Dr. Reddy's Laboratories, and Lupin Pharmaceuticals. In the API manufacturing sector, competitors include Aurobindo Pharma and Sun Pharmaceutical Industries. Kopran's focus on quality, regulatory compliance, and a diverse product portfolio positions it favorably in the market.

Kopran Limited's key differentiators include its extensive experience of over 60 years in the pharmaceutical industry, a diverse product portfolio covering multiple therapeutic categories, and manufacturing facilities accredited by international regulatory bodies. The company's commitment to research and development, along with its focus on quality and affordability, further distinguishes it in the global pharmaceutical market.

Kopran Limited's current strategic direction emphasizes the development and manufacturing of both generic formulations and APIs, with a focus on expanding its presence in regulated and emerging markets. The company's future outlook includes leveraging its R&D capabilities to introduce new products, enhancing its manufacturing processes, and strengthening its global distribution network to meet the growing demand for affordable and high-quality pharmaceutical products.

Kopran Limited has a strong track record in the pharmaceutical industry, with a consistent export volume of $7.3 million USD across 276 shipments from 2022 to 2026. The company's portfolio concentration, with the top five products accounting for 94.6% of exports, indicates a focused approach to its product offerings. Kopran's adherence to international quality standards and regulatory compliance further enhances its reliability as a supplier.

Importers should verify the following certifications when considering Kopran Limited as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulatory standards.

• WHO GMP Certification: Verify the World Health Organization's Good Manufacturing Practices certification to ensure adherence to international quality standards.

• EU GMP Certification: Check the European Union's Good Manufacturing Practices certification to confirm compliance with European regulatory requirements.

• ISO Certification: Ensure the company holds relevant ISO certifications, indicating adherence to international quality management standards.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Kopran Limited directly.

When conducting due diligence on Kopran Limited, consider the following steps:

• Regulatory Compliance: Verify the company's certifications and approvals from relevant regulatory authorities, such as the FDA, WHO, EU GMP, and ISO.

• Financial Health: Review the company's financial statements to assess profitability, revenue trends, and financial stability.

• Product Portfolio: Evaluate the diversity and quality of the company's product offerings, including therapeutic categories and dosage forms.

• Supply Chain Reliability: Assess the company's supply chain capabilities, including manufacturing capacity, lead times, and logistics.

• Market Reputation: Research the company's reputation in the market, including customer reviews, industry recognition, and any history of regulatory issues.

Red flags to watch